Early detection of cancer has the potential to radically reshape healthcare costs, outcomes, and insurance models. In this session, we'll explore how multi-cancer early detection (MCED) can move the industry from late-stage treatment to proactive risk management. We’ll examine the economic and actuarial implications of catching cancers earlier, the role of genomics in underwriting, and how payers, life insurers, and employers can adopt precision screening to reduce claims, extend longevity, and create new value. This is not just innovation in diagnostics — it’s a blueprint for insuring a healthier future.